Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology, 2006, 24(24):3984-3990. [7] Miller et al. The phase 3...
Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology, 2006, 24(24):3984-3990. [7] Miller et al. The phase 3 COU-AA-302 study of Abiraterone acetate plus prednisone ...
Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology, 2006, 24(24):3984-3990. [7] Miller et al. The phase 3 COU-AA-302 study of Abiraterone acetate plus prednisone ...
大量研究结果均证实,前列腺癌患者越早开始阿比特龙治疗,治疗效果越好,生存获益越大。 参考文献[1] Meissner H et al. Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9...
[2]Fizazi K, Tran N, Fein L, Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med.2017 Jul 27;377(4):352-360 *此文仅用于向医学人士提供科学信息,不代表本平台观点
文章标题:Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring 期刊:European Urology 影响因子:17.947 发布时间:2020年8月 ...
[3] 1.Chi K M, et al. Final analysis results from TITAN: a phase 3 study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy. J Clin Oncol 39, 2021 (suppl 6; abstr 11). ...
[2]Fizazi K, Tran N, Fein L, Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med.2017 Jul 27;377(4):352-360 *此文仅用于向医学人士提供科学信息,不代表本平台观点
[2] Meissner H et al. Absolute Prostate-Specific Antigen Value After Androgen.Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology, 2006, 24(24):3984-3990. ...
6. Alicia K. Morgans, et al. Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS. ASCO 2022. Poster 228. 7. Wenzel M, et al. Prostate Cancer Prostatic Dis. 2021 May 30. ...